EP2222162A4 - Inhibiteurs myristate à petites molécules de bcr-abl et procédés d'utilisation - Google Patents
Inhibiteurs myristate à petites molécules de bcr-abl et procédés d'utilisationInfo
- Publication number
- EP2222162A4 EP2222162A4 EP08857261A EP08857261A EP2222162A4 EP 2222162 A4 EP2222162 A4 EP 2222162A4 EP 08857261 A EP08857261 A EP 08857261A EP 08857261 A EP08857261 A EP 08857261A EP 2222162 A4 EP2222162 A4 EP 2222162A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- bcr
- abl
- methods
- small molecule
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 title 1
- -1 Small molecule myristate Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229940105132 myristate Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21184206.7A EP3912973A3 (fr) | 2007-11-28 | 2008-11-28 | Inhibiteurs de myristate de bcr-abl à petite molécule et procédés d'utilisation |
EP19170210.9A EP3536687B8 (fr) | 2007-11-28 | 2008-11-28 | Inhibiteurs de myristate de bcr-abl à petite molécule et procédés d'utilisation |
EP16197611.3A EP3150593B8 (fr) | 2007-11-28 | 2008-11-28 | Petite molécules en tant que inhibiteurs de myristate de bcr-abl et procédés d'utilisation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US446207P | 2007-11-28 | 2007-11-28 | |
PCT/US2008/013219 WO2009073153A2 (fr) | 2007-11-28 | 2008-11-28 | Inhibiteurs myristate à petites molécules de bcr-abl et procédés d'utilisation |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16197611.3A Division EP3150593B8 (fr) | 2007-11-28 | 2008-11-28 | Petite molécules en tant que inhibiteurs de myristate de bcr-abl et procédés d'utilisation |
EP21184206.7A Division EP3912973A3 (fr) | 2007-11-28 | 2008-11-28 | Inhibiteurs de myristate de bcr-abl à petite molécule et procédés d'utilisation |
EP19170210.9A Division EP3536687B8 (fr) | 2007-11-28 | 2008-11-28 | Inhibiteurs de myristate de bcr-abl à petite molécule et procédés d'utilisation |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2222162A2 EP2222162A2 (fr) | 2010-09-01 |
EP2222162A4 true EP2222162A4 (fr) | 2012-01-18 |
EP2222162B1 EP2222162B1 (fr) | 2016-11-16 |
Family
ID=40718412
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21184206.7A Pending EP3912973A3 (fr) | 2007-11-28 | 2008-11-28 | Inhibiteurs de myristate de bcr-abl à petite molécule et procédés d'utilisation |
EP19170210.9A Active EP3536687B8 (fr) | 2007-11-28 | 2008-11-28 | Inhibiteurs de myristate de bcr-abl à petite molécule et procédés d'utilisation |
EP16197611.3A Active EP3150593B8 (fr) | 2007-11-28 | 2008-11-28 | Petite molécules en tant que inhibiteurs de myristate de bcr-abl et procédés d'utilisation |
EP08857261.5A Active EP2222162B1 (fr) | 2007-11-28 | 2008-11-28 | Inhibiteurs myristate à petites molécules de bcr-abl et procédés d'utilisation |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21184206.7A Pending EP3912973A3 (fr) | 2007-11-28 | 2008-11-28 | Inhibiteurs de myristate de bcr-abl à petite molécule et procédés d'utilisation |
EP19170210.9A Active EP3536687B8 (fr) | 2007-11-28 | 2008-11-28 | Inhibiteurs de myristate de bcr-abl à petite molécule et procédés d'utilisation |
EP16197611.3A Active EP3150593B8 (fr) | 2007-11-28 | 2008-11-28 | Petite molécules en tant que inhibiteurs de myristate de bcr-abl et procédés d'utilisation |
Country Status (12)
Country | Link |
---|---|
US (7) | US8921336B2 (fr) |
EP (4) | EP3912973A3 (fr) |
JP (2) | JP5779778B2 (fr) |
KR (1) | KR20100130583A (fr) |
CN (3) | CN104327084B (fr) |
AU (1) | AU2008331867B2 (fr) |
BR (1) | BRPI0819453A2 (fr) |
CA (1) | CA2707046A1 (fr) |
EA (1) | EA019869B1 (fr) |
ES (3) | ES2610190T3 (fr) |
MX (3) | MX2010005671A (fr) |
WO (1) | WO2009073153A2 (fr) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100130583A (ko) * | 2007-11-28 | 2010-12-13 | 다나-파버 캔서 인스티튜트 인크. | Bcr-abl의 소 분자 미리스테이트 억제제 및 이의 사용 방법 |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
SI2300013T1 (en) | 2008-05-21 | 2018-03-30 | Adriad Pharmacaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
EP2962566A1 (fr) | 2008-10-31 | 2016-01-06 | Genentech, Inc. | Composés inhibiteurs de jak de pyrazolopyrimidine et procédés |
UA110324C2 (en) | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
TW201111385A (en) * | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
UY33241A (es) * | 2010-02-26 | 2011-09-30 | Boehringer Ingelheim Int | ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?. |
BR112012021364A2 (pt) * | 2010-02-26 | 2016-10-25 | Boehringer Ingelheim Int | "compostos cicloalquila contendo tienopirimidinas e composições farmacêuticas". |
US8853193B2 (en) * | 2010-02-26 | 2014-10-07 | Boehringer Ingelheim International Gmbh | Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions |
WO2011144742A1 (fr) | 2010-05-21 | 2011-11-24 | Chemilia Ab | Nouveaux dérivés de pyrimidine |
EP2616072A1 (fr) | 2010-09-15 | 2013-07-24 | F.Hoffmann-La Roche Ag | Composés d'azabenzothiazole, compositions et procédés d'utilisation |
MX2013005445A (es) | 2010-11-19 | 2013-07-29 | Hoffmann La Roche | Pirazolopiridinas y el uso de pirazolopiridinas como inhibidores de tirosina cinasa 2 (tyk2). |
WO2012088266A2 (fr) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3 |
DK2688883T3 (en) | 2011-03-24 | 2016-09-05 | Noviga Res Ab | pyrimidine |
AU2012250517B2 (en) | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
EP2548878A1 (fr) * | 2011-07-21 | 2013-01-23 | Laboratorios Del. Dr. Esteve, S.A. | Composés de pyrazolo[3,4-d]pyrimidine, leur préparation et utilisation en tant que ligands sigma |
EP2809671B1 (fr) * | 2012-01-30 | 2016-01-13 | Cephalon, Inc. | Dérivés imidazo [4,5-b]pyridine comme modulateurs d'alk et de jak pour le traitement de troubles prolifératifs |
US20150166591A1 (en) | 2012-05-05 | 2015-06-18 | Ariad Pharmaceuticals, Inc. | Methods and compositions for raf kinase mediated diseases |
AR091424A1 (es) | 2012-06-13 | 2015-02-04 | Incyte Corp | Compuestos triciclicos sustituidos como inhibidores de receptores del factor de crecimiento del fibroplasto (fgfr) |
CN102746308B (zh) * | 2012-07-09 | 2014-12-31 | 四川大学 | 别嘌醇衍生物及其制备方法和用途 |
CN102746306B (zh) * | 2012-07-09 | 2014-11-19 | 四川国康药业有限公司 | 别嘌醇类衍生物及其制备方法和用途 |
WO2014026125A1 (fr) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Dérivés de pyrazine en tant qu'inhibiteurs de fgfr |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
WO2014152716A1 (fr) * | 2013-03-15 | 2014-09-25 | President And Fellows Of Harvard College | Composés hétérocycliques substitués pour le traitement ou la prévention d'infections virales |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
TWI649318B (zh) | 2013-04-19 | 2019-02-01 | 英塞特控股公司 | 作為fgfr抑制劑之雙環雜環 |
SG11201609830RA (en) | 2014-05-23 | 2016-12-29 | Hoffmann La Roche | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors |
DK3172213T3 (da) | 2014-07-21 | 2021-12-13 | Dana Farber Cancer Inst Inc | Makrocykliske kinasehæmmere og anvendelser deraf |
CA2954186A1 (fr) | 2014-07-21 | 2016-01-28 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs d'imidazolyl kinase et leurs utilisations |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
WO2016134294A1 (fr) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
MX2017010673A (es) | 2015-02-20 | 2018-03-21 | Incyte Corp | Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr). |
WO2016173557A1 (fr) * | 2015-04-30 | 2016-11-03 | 中国科学院上海药物研究所 | Composé ayant une activité d'inhibition de kinase, procédé de préparation et utilisations |
CN105561040A (zh) * | 2016-02-24 | 2016-05-11 | 梁功 | 一种治疗偏瘫的中药组合物 |
CN105777657A (zh) * | 2016-03-01 | 2016-07-20 | 张宏业 | 一种治疗偏瘫的药物组合物 |
US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
AU2017291812B2 (en) | 2016-07-05 | 2023-12-14 | Dana-Farber Cancer Institute, Inc. | Bicyclic urea kinase inhibitors and uses thereof |
WO2018053373A1 (fr) | 2016-09-16 | 2018-03-22 | The General Hospital Corporation | Utilisations d'inhibiteurs de kinase inductible par un sel (sik) pour traiter l'ostéoporose |
AU2017363257B2 (en) * | 2016-11-22 | 2021-08-19 | Dana-Farber Cancer Institute, Inc. | Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use |
KR20190120331A (ko) | 2017-02-28 | 2019-10-23 | 더 제너럴 하스피탈 코포레이션 | Sik 억제제로서의 피리미도피리미디논의 용도 |
KR20200010390A (ko) | 2017-05-22 | 2020-01-30 | 에프. 호프만-라 로슈 아게 | 치료 화합물 및 조성물, 및 이의 사용 방법 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
MA52494A (fr) | 2018-05-04 | 2021-03-10 | Incyte Corp | Formes solides d'un inhibiteur de fgfr et leurs procédés de préparation |
CA3099116A1 (fr) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Sels d'un inhibiteur de fgfr |
US20210130352A1 (en) * | 2018-06-21 | 2021-05-06 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
CA3118752A1 (fr) | 2018-11-09 | 2020-05-14 | Vivace Therapeutics, Inc. | Composes bicycliques |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
WO2020214734A1 (fr) | 2019-04-16 | 2020-10-22 | Vivace Therapeutics, Inc. | Composés bicycliques |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
PE20221085A1 (es) | 2019-10-14 | 2022-07-05 | Incyte Corp | Heterociclos biciclicos como inhibidores de fgfr |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
JP2023505258A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Fgfr阻害剤としての三環式複素環 |
US11407750B2 (en) | 2019-12-04 | 2022-08-09 | Incyte Corporation | Derivatives of an FGFR inhibitor |
US20240025913A1 (en) * | 2020-10-21 | 2024-01-25 | Vivace Therapeutics, Inc. | Tertiary carboxamide compounds |
AU2022288713A1 (en) * | 2021-06-07 | 2023-12-21 | Dana-Farber Cancer Institute, Inc. | Inhibitors of ttbk1 |
AR126102A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998012184A1 (fr) * | 1996-09-19 | 1998-03-26 | Nippon Soda Co., Ltd. | Composes de pyrimidine, procede de preparation correspondant et agents de lutte antiparasitaire |
WO2002047690A1 (fr) * | 2000-12-12 | 2002-06-20 | Cytovia, Inc. | 2-aryl-4-arylaminopyrimidines substituees et analogues en tant qu'activateurs de caspases et qu'inducteurs d'apoptose, et utilisation associee |
US20040132786A1 (en) * | 2002-12-20 | 2004-07-08 | Irm Llc, A Delaware Limited Liability Company | Differential tumor cytotoxicity compounds and compositions |
US20050014753A1 (en) * | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
WO2006034473A2 (fr) * | 2004-09-23 | 2006-03-30 | Reddy Us Therapeutics, Inc. | Nouveaux composes de pyrimidine, leur procede de preparation, et compositions les contenant |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
CN1237177A (zh) * | 1996-11-27 | 1999-12-01 | 辉瑞大药厂 | 稠合的二环嘧啶衍生物 |
BR9814018A (pt) * | 1997-11-11 | 2000-09-26 | Pfizer Prod Inc | Derivados de tienopirimidina e tienopiridina úteis como agentes anticâncer |
SK286640B6 (sk) * | 1998-06-19 | 2009-03-05 | Pfizer Products Inc. | Pyrol [2,3-d] pyrimidínová zlúčenina, jej použitie na výrobu liečiva, farmaceutická kompozícia s jej obsahom, použitie jej kombinácie s ďalšími činidlami a súpravy s jej obsahom na výrobu liečiva |
US6258820B1 (en) * | 1999-03-19 | 2001-07-10 | Parker Hughes Institute | Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines |
KR100790202B1 (ko) | 2000-07-06 | 2007-12-31 | 노벨리스 인코퍼레이티드 | 핀용 알루미늄 합금 박 제조방법 |
CZ294535B6 (cs) * | 2001-08-02 | 2005-01-12 | Ústav Experimentální Botaniky Avčr | Heterocyklické sloučeniny na bázi N6-substituovaného adeninu, způsoby jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující |
WO2003031406A2 (fr) * | 2001-10-12 | 2003-04-17 | Irm Llc | Squelettes d'inhibiteurs de kinase et leurs methodes de preparation |
BR0306982A (pt) | 2002-01-17 | 2004-10-26 | Neurogen Corp | Composto ou um sal deste farmaceuticamente aceitável, composição farmacêutica, métodos para reduzir a condutância de cálcio de um receptor da capsaicina celular, para inibir a ligação de ligando vanilóide a um receptor da capsaicina in vitro e em um paciente, para tratar uma condição responsiva à modulação do receptor da capsaicina em um paciente, para tratar a dor em um paciente, para tratar coceira em um paciente, para tratar tosse ou soluço em um paciente, promover a perda de peso em um paciente obeso, e para determinar a presença ou ausência de receptor da capsaicina em uma amostra, preparação farmacêutica embalada, e, uso de um composto |
TW200400034A (en) * | 2002-05-20 | 2004-01-01 | Bristol Myers Squibb Co | Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors |
CN1798734A (zh) * | 2003-04-04 | 2006-07-05 | Irm责任有限公司 | 作为蛋白激酶抑制剂的新化合物和组合物 |
EP1651648A4 (fr) * | 2003-07-29 | 2009-09-02 | Irm Llc | Composes et compositions utilises en tant qu'inhibiteurs des proteines kinases |
US7338957B2 (en) * | 2003-08-28 | 2008-03-04 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
GB0326168D0 (en) * | 2003-11-10 | 2003-12-17 | Arrow Therapeutics Ltd | Chemical compounds |
US20070009977A1 (en) | 2005-01-12 | 2007-01-11 | Boyce James P | Kinase-directed, activity-based probes |
WO2006124874A2 (fr) * | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibiteurs de la b-raf kinase |
JP5301986B2 (ja) * | 2005-06-22 | 2013-09-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物用のチエノピリミジン類 |
EP2044086A2 (fr) * | 2006-06-30 | 2009-04-08 | Janssen Pharmaceutica N.V. | Modulateurs de trpv1 à base de thiazolopyrimidine |
KR20100130583A (ko) * | 2007-11-28 | 2010-12-13 | 다나-파버 캔서 인스티튜트 인크. | Bcr-abl의 소 분자 미리스테이트 억제제 및 이의 사용 방법 |
-
2008
- 2008-11-28 KR KR1020107013953A patent/KR20100130583A/ko not_active Application Discontinuation
- 2008-11-28 EP EP21184206.7A patent/EP3912973A3/fr active Pending
- 2008-11-28 ES ES08857261.5T patent/ES2610190T3/es active Active
- 2008-11-28 BR BRPI0819453-0A2A patent/BRPI0819453A2/pt not_active IP Right Cessation
- 2008-11-28 JP JP2010536015A patent/JP5779778B2/ja active Active
- 2008-11-28 CA CA2707046A patent/CA2707046A1/fr not_active Abandoned
- 2008-11-28 AU AU2008331867A patent/AU2008331867B2/en not_active Ceased
- 2008-11-28 MX MX2010005671A patent/MX2010005671A/es active IP Right Grant
- 2008-11-28 EA EA201070595A patent/EA019869B1/ru not_active IP Right Cessation
- 2008-11-28 ES ES16197611T patent/ES2734288T3/es active Active
- 2008-11-28 EP EP19170210.9A patent/EP3536687B8/fr active Active
- 2008-11-28 WO PCT/US2008/013219 patent/WO2009073153A2/fr active Application Filing
- 2008-11-28 CN CN201410497692.5A patent/CN104327084B/zh active Active
- 2008-11-28 EP EP16197611.3A patent/EP3150593B8/fr active Active
- 2008-11-28 CN CN201410497500.0A patent/CN104311563B/zh active Active
- 2008-11-28 CN CN200880123462.5A patent/CN101917849B/zh active Active
- 2008-11-28 ES ES19170210T patent/ES2893580T3/es active Active
- 2008-11-28 US US12/745,496 patent/US8921336B2/en active Active
- 2008-11-28 EP EP08857261.5A patent/EP2222162B1/fr active Active
-
2012
- 2012-03-16 MX MX2012003311A patent/MX2012003311A/es not_active Application Discontinuation
- 2012-03-16 MX MX2012003309A patent/MX2012003309A/es not_active Application Discontinuation
-
2014
- 2014-10-03 JP JP2014204682A patent/JP5941513B2/ja active Active
- 2014-11-13 US US14/540,919 patent/US9670214B2/en active Active
-
2017
- 2017-04-28 US US15/582,004 patent/US20170349595A1/en not_active Abandoned
-
2018
- 2018-10-25 US US16/170,921 patent/US10787455B2/en active Active
-
2020
- 2020-07-20 US US16/933,095 patent/US11254682B2/en active Active
-
2022
- 2022-01-12 US US17/574,132 patent/US11932646B2/en active Active
-
2024
- 2024-01-24 US US18/421,738 patent/US20240158403A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998012184A1 (fr) * | 1996-09-19 | 1998-03-26 | Nippon Soda Co., Ltd. | Composes de pyrimidine, procede de preparation correspondant et agents de lutte antiparasitaire |
WO2002047690A1 (fr) * | 2000-12-12 | 2002-06-20 | Cytovia, Inc. | 2-aryl-4-arylaminopyrimidines substituees et analogues en tant qu'activateurs de caspases et qu'inducteurs d'apoptose, et utilisation associee |
US20040132786A1 (en) * | 2002-12-20 | 2004-07-08 | Irm Llc, A Delaware Limited Liability Company | Differential tumor cytotoxicity compounds and compositions |
US20050014753A1 (en) * | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
WO2006034473A2 (fr) * | 2004-09-23 | 2006-03-30 | Reddy Us Therapeutics, Inc. | Nouveaux composes de pyrimidine, leur procede de preparation, et compositions les contenant |
Non-Patent Citations (1)
Title |
---|
ADRIAN FRANCISCO J ET AL: "Allosteric inhibitors of Bcr-abl-dependent cell proliferation", NATURE CHEMICAL BIOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 2, no. 2, 1 February 2006 (2006-02-01), pages 95 - 102, XP009086418, ISSN: 1552-4450, DOI: 10.1038/NCHEMBIO760 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2222162A4 (fr) | Inhibiteurs myristate à petites molécules de bcr-abl et procédés d'utilisation | |
HK1254895A1 (zh) | 苄基苯衍生物及使用方法 | |
IL275881B (en) | Methods for using alpha1–il antibodies | |
IL240771A0 (en) | Benzoxazole kinase inhibitors and methods of use | |
IL198397A0 (en) | Anilinopiperazine derivatives and methods of use thereof | |
HK1147254A1 (en) | 5-anilinoimidazopyridines and methods of use 5- | |
HK1160119A1 (en) | Kinase inhibitors and methods of use | |
IL196956A0 (en) | Aza-benzofuranyl compounds and methods of use | |
EP2252293A4 (fr) | Inhibiteurs de kinases, et procédés d utilisation associés | |
EP2023718A4 (fr) | Composés de ligand de créatine et procédés d'utilisation correspondants | |
EP2191458A4 (fr) | Dispositifs portés sur le doigt et procédés d'utilisation associés | |
IL197060A0 (en) | Aza-benzothiophenyl compounds and methods of use | |
EP2021555A4 (fr) | Élément structurel et procédés d'utilisation associés | |
ZA200808017B (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
IL206125A0 (en) | Azaindolizines and methods of use | |
ZA201000183B (en) | Quinazolinone compounds and methods of use thereof | |
IL206891A0 (en) | Therapeutic inhibitors of pai-1 function and methods of their use | |
EP2126056A4 (fr) | Inhibiteurs de la famille des paramyxovirus et procédés d'utilisation de ceux-ci | |
EP2245020A4 (fr) | Dérivés de thiazolylidine urée et d'amides et leurs méthodes d'utilisation | |
ZA200900896B (en) | Aza-benzofuranyl compounds and methods of use | |
GB2459413A8 (en) | Perfluoroparacyclophane and methods of synthesis and use thereof | |
ZA200901009B (en) | Aza-benzothiophenyl compounds and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20100622 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: WOJCIECHOWSKI, AMY Inventor name: OKRAM, BARUN Inventor name: CHANG, JAE WON Inventor name: GRAY, NATHANAEL, S. Inventor name: DENG, XIANMING Inventor name: ZHANG, JIANMING |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: DANA-FARBER CANCER INSTITUTE, INC. |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1147910 Country of ref document: HK |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: DANA-FARBER CANCER INSTITUTE, INC. |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20111219 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A01N 43/04 20060101AFI20111213BHEP |
|
17Q | First examination report despatched |
Effective date: 20121114 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: THE SCRIPPS RESEARCH INSTITUTE Owner name: DANA-FARBER CANCER INSTITUTE, INC. |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602008047453 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A01N0043040000 Ipc: C07D0403120000 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 495/04 20060101ALI20160524BHEP Ipc: A61K 31/7076 20060101ALI20160524BHEP Ipc: A61K 31/517 20060101ALI20160524BHEP Ipc: C07D 403/12 20060101AFI20160524BHEP Ipc: A61K 31/519 20060101ALI20160524BHEP Ipc: C07D 487/04 20060101ALI20160524BHEP Ipc: C07D 239/94 20060101ALI20160524BHEP Ipc: C07D 471/04 20060101ALI20160524BHEP Ipc: C07D 403/06 20060101ALI20160524BHEP Ipc: A61K 31/52 20060101ALI20160524BHEP Ipc: C07H 19/16 20060101ALI20160524BHEP Ipc: C07D 239/42 20060101ALI20160524BHEP Ipc: C07D 403/04 20060101ALI20160524BHEP Ipc: A61K 45/06 20060101ALI20160524BHEP Ipc: C07D 417/04 20060101ALI20160524BHEP Ipc: A61K 31/5377 20060101ALI20160524BHEP Ipc: C07D 473/34 20060101ALI20160524BHEP |
|
INTG | Intention to grant announced |
Effective date: 20160624 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
GRAR | Information related to intention to grant a patent recorded |
Free format text: ORIGINAL CODE: EPIDOSNIGR71 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
INTG | Intention to grant announced |
Effective date: 20161006 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PK Free format text: DAS PRIORITAETSAKTENZEICHEN WURDE BERICHTIGT: US 4462 P / 28.11.2007 Ref country code: AT Ref legal event code: REF Ref document number: 845795 Country of ref document: AT Kind code of ref document: T Effective date: 20161215 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602008047453 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602008047453 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20161116 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 845795 Country of ref document: AT Kind code of ref document: T Effective date: 20161116 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2610190 Country of ref document: ES Kind code of ref document: T3 Effective date: 20170426 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170217 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170216 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161130 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170316 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1147910 Country of ref document: HK |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161130 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161130 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602008047453 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170216 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161130 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10 |
|
26N | No opposition filed |
Effective date: 20170817 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161128 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20081128 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161128 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230526 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20231019 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20231208 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20231026 Year of fee payment: 16 Ref country code: FR Payment date: 20231024 Year of fee payment: 16 Ref country code: DE Payment date: 20231017 Year of fee payment: 16 |